Semaglutide (link:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html) is a drug for the treatment of type 2 diabetes and belongs to the insulin-like peptide-1 receptor agonist (GLP-1 RA). Chemical formula C187H291N45O59, CAS CAS 910463-68-2. It is a white to off-white powder. It is soluble in water and forms a clear to slightly cloudy solution with a solubility in water of about 10 mg/mL, and can also be dissolved in some organic solvents such as alcohols and dimethyl sulfoxide. It is a synthetic similar peptide. In the chemical structure of semaglutide, there is also a cysteine residue, which is connected to other amino acid residues by disulfide bonds. Relatively stable under normal drug storage conditions. It can be stored for a long time under refrigerated conditions (2-8 degrees Celsius). The finished drug of this chemical product has many clinical uses, but the product produced by Shaanxi Chuchan Chemical Co., Ltd. is a primary chemical product and is only used for scientific research.
Semaglutide is an insulin-like peptide-1 receptor agonist (GLP-1 RA), mainly used in the treatment of type 2 diabetes. In addition to treating diabetes, semaglutide is being investigated for several other potential uses.
1. Diabetes treatment:
Semaglutide is a long-acting GLP-1 receptor agonist that reduces blood sugar levels by mimicking the action of insulin-like peptide-1 (GLP-1) produced in the body. It stimulates the secretion of insulin, inhibits the secretion of glucagon, and slows the emptying of the gastrointestinal tract, thereby reducing the rise in blood sugar after food intake. The long-acting nature of semaglutide allows it to provide sustained glycemic control as a once-weekly injection.
2. Weight management:
In addition to treating diabetes, semaglutide is also used for weight management. Clinical trials have shown that obese patients treated with semaglutide can achieve significant weight loss compared to placebo. Semaglutide works by suppressing appetite and increasing satiety, thereby reducing energy intake. Therefore, it is considered as a potential therapeutic tool for obesity.
3. Cardiovascular protection:
Semaglutide has also shown a protective effect on the cardiovascular system. In the cardiovascular safety trial, diabetic patients treated with semaglutide had a significantly lower risk of cardiovascular events (such as heart attack, stroke) compared with placebo. This indicates that semaglutide may have the effect of reducing the risk of cardiovascular disease, which may be related to improving insulin resistance, reducing insulin resistance and improving blood fat metabolism.
4. Chronic kidney disease treatment:
Recent clinical trials have shown that semaglutide also shows potential in the treatment of chronic kidney disease. Type 2 diabetic patients treated with semaglutide not only have good blood sugar control, but also have significant improvement in renal function indicators. In addition, semaglutide reduces urinary albumin excretion, an indicator of kidney disease.
5. Lipid metabolism disorder:
Semaglutide also improves lipid metabolism and lowers blood triglyceride and cholesterol levels. This is especially important for diabetics, as they often have abnormal lipid metabolism.
Semaglutide is a drug that belongs to the class of insulin-like peptide-1 receptor agonists (GLP-1 RA). But it is also a chemical product. As a professional chemical company, we have also conducted detailed research on its chemical properties when studying the use of this product. After many tests, we have the following properties:
1. Chemical reaction:
- Hydrolysis: Semaglutide undergoes a hydrolysis reaction in water, and its peptide chain is broken into amino acid residues by water molecules. This hydrolysis reaction may occur in vitro or in vivo.
- Protease Degradation: Semaglutide may be degraded by proteases in vivo. Proteases further cleave the peptide chain into smaller fragments, eventually forming amino acid residues.
- Oxidation: Semaglutide contains multiple sulfite groups (S-S), which may be oxidized to disulfide bonds (S-S) under oxidative conditions.
- Acetylase-catalyzed reaction: The acetate linkage (Ac-O-) in Semaglutide may be hydrolyzed to the corresponding hydroxyl compound by acetate-catalyzed enzymes.
2. Pharmacokinetics and in vivo reactions:
- Absorption: Semaglutide is administered by subcutaneous injection. This route of administration promotes the absorption of the drug and achieves the highest concentration in the blood. After injection, semaglutide is released slowly, providing sustained action.
- Distribution: In blood circulation, Semaglutide can bind to plasma proteins. It can also reach target tissues and organs through blood circulation.
- Metabolism: Semaglutide is metabolized by the liver and other tissues mainly through the metabolism of insulinase and other enzymes. These enzymes degrade the peptide chain of semaglutide and convert it into amino acid residues or smaller fragments.
- Excretion: Semaglutide is excreted via the kidneys and feces. Semaglutide that has not been metabolized or absorbed is excreted unchanged in the urine.
3. Drug interactions:
- Insulin and oral hypoglycemic drugs: When used concomitantly with insulin and oral hypoglycemic drugs, semaglutide may enhance the hypoglycemic effect of these drugs. Therefore, the dosage of insulin and oral hypoglycemic drugs should be carefully adjusted before using semaglutide.
- Digestive Enzyme Inhibitors: Digestive enzyme inhibitors (such as orlistat) may affect the absorption of semaglutide. Therefore, it may be necessary to adjust the dose or timing of semaglutide when these drugs are used concomitantly.